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Physostigmine's effect on diminished fetal heart rate variability caused by scopolamine, meperidine and propiomazine Frank H. Boehm, Ay Egilmez, Bradley E. Smith
Departments of Obstetrics and Gynecology arid Anesthesiology, Vanderbilt University Hospital, Nashville, Tennessee 37232, USA Fetal heart rate (F.H.R.) variability has been recognized for many years äs a useful guide in assessing fetal well being [4] . While normal fetal heart rate variability is associated with fetal health, a loss of this variability, especially when associated withlate decelerationorsevere variable deceleration patterns, has been shown to be an omnious sign of fetal distress [2] . Since drugs such äs meperidine, propiomazine and scopolamine often result in a loss of fetal heart rate variability [1], secondary to their central autonomic suppression, this Parameter of fetal heart rate monitoring often cannot be assessed accurately when these drugs are present in the patient in labor. Because of this, it might be beneflcial to attempt to reverse this drug induced loss of fetal heart rate variability if, during labor, confusion arose äs to its importance in assessing fetal distress. Since physostigmine can be used to reverse the delirium resulting when scopolamine is given to an adult [3] and since it is a drug well known for its anticholinesterase activity, physostigmine was given to patients in labor previously given scopolamine alone and meperidine and propiomazine in combination to ascertain the effect on reversing the loss of fetal heart rate variability caused by the administration of these drugs.
Materials and methods
Seventeen healthy women between 39 and 42 weeks gestation in early labor who had received no medication previously were utilized for this study. The age ränge of the patients studied was 15 to 33 while parity and ränge was 0 to 3. Patients were screened for allergies to drugs äs well äs history of asthma because of physostigmine's Potential adverse effect in patients with these Problems. Internal fetal heart rate monitoring was accomplished by the use of a scalp electrode attached to a fetal monitor* after artificial or spontaneous rupture of the amniotic-membranes. Maternal blood pressure and pulse were recorded at two minute intervals and base line fetal heart rate variability was recorded and classified äs previously described [1] . All patients were noted to display normal fetal heart rate variability prior to drug administration. Total scopolamine doses of 0.65 to 1.08 mgs was given intravenously to 7 patients followed by 2 to 5 mgs of physostigmine intravenously after establishing a decrease of fetal heart rate variability. This same procedure was foUowed in 10 patients after administration of meperidine, 50 mgs, and propiomazine, 20 mgs, intravenously. Maternal blood pressure, pulse, äs well äs fetal heart rate variability was then assessed for 60 minutes following the infusion of physostigmine.
Results
Scopolamine in doses of 0.65 to l .08 mgs diminished fetal heart rate variability in all 7 patients and physostigmine reversed this loss of fetal heart rate variability in all 7 patients within 4 to 17 minutes (average 9 min.) (Tab. I, Figs. 1-3 
Fetal heart rate tracing revealing loss of variability after scopolomine infusion. Fig. 3 . Fetal heart rate tracing revealing abrupt return to normal variability 11 minutes after infusion of the first 2 mg dose of physostigmine.
patients studied although l patient did sustain an elevation of 40 mm Hg in systolic pressure which returned to the base line within 14 minutes (Fig. 4) . Maternal pulse rate, already elevated sligh y by scopolamine, was reduced to 56obeats per minute in l patient (Fig. 4) . No adverse systemic reactions to either scopolamine or physostigmine was noted in any of the patients. Fetal scalp samples obtained within 10 minutes after physostigmine administration was performed in 2 patients and were found to be within normal limits, however no further attempts were made to follow fetal scalp pH because of fetal manipulation effects on fetal heart rate variability. No pathological fetal heart rate patterns or significant fetal heart rate base line changes were recorded during the study. All patients delivered normal term neonates with 5 minute » Apgar scores of 8,9 or 10. The 10 patients who were given meperidine and propiomazine whose fetal heart rate variability was diminished sufficient to ascertain physostigmine's effect were noted to show an increase in fetal heart rate base line variability within 3 to 17 minutes (average 9.1 min.) after the administration of 3-4 mgs of physostigmine intravenously (Tab. I, Figs. 5-10). While one patient's pulse decreased 40 beats per minute within 5 minutes of physostigmine's infusion, no patient's pulse rate feil below 60 beats per minute. Most pulse rates remained stable, feil slighfly, or occasionally •ι.· «. ,.ι τ ι. ,".,..,-..n _^i ".. 
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Figs. 9 & 10. Fetal heart rate tracings revealing abrupt return to normal variability minutes after physostigmine inf sion.
were noted to be elevated following physostigmine inf sion. There were no significant blood pressure changes recorded in this group of patients. Again, no pathological fetal heart rate patterns were recorded any time during the study and all patients delivered normal term neonates with 5 minute Apgar scores of 8,9 or 10.
Comments
Physostigmine, an anticholinesterase drug and capable of crossing the blood brain barrier, has been noted to be able to reverse the delirium produced by atropine like drugs [3] . Its effect, however, on fetal heart rate variability has not been previously studied. It seems tenable from this study that physostigmine does cross the placental barrier and enters the fetal circulation and that this usually occurs within 3 to 17 minutes with an average of approximately 9 minutes. The possibility of utilizing this drug to determine placental functionin the future is intriguing. In the healthy fetus the loss of fetal heart rate variability caused by scopolamine, meperidine orpropiomazine can be reversed by the use of physostigmine and thisreversal seems abrupt and clinically measurable on the fetal monitor print out. Matemal responses to blood pressure and pulse after inf sion.of physostigmine are minimal and are in agreement with other studies. SMILER, et al. recorded no adverse effects of physostigmine in doses of 3 mg intravenously on the fetus or mother and noted no fetal or maternal bradycardia [3] , Matemal br dycardia (less than 50 beats per minute) was not noted in any of our patients studied, however, one was noted to have a pulse rate of 56 beats per minute. This patient was given a total of 4 mg of physostigmine. The fact that physostigmine can reverse the loss of fetal heart rate variability caused by meperidine and propiomazine support the fact that such depression of fetal heart rate variability caused by these drugs may be based on their atropine like properties. Studies to ascertain physostigmine's effect on fetal heart rate variability in animals who are noted to display loss of fetal heart rate variability secondary to induced fetal distress will need to be performed in the future" If no such retum of fetal heart rate variability is noted in this experimental Situation it wouldseem tenable to use the drug, physostigmine, äs a clinical test to distinguish the fetus in distress from one whose fetal heart rate variability is diminished secondary to drug administration. Therefore, in the sedated patient who displays a questionable pathological fetal heart rate deceleration, a quick return to normal variability after administration of physostigmine, might obviate the need for fetal scalp sampling or other obstetrical Intervention. Because physostigmine might cause further physiological embarrassment in the already acidotic or hypoxic Situation, human use to differentiate fetal distress from drug effect is not recommended until further studies have clarified this possibility.
Summary
Physostigmine was given to 17 patients in labor, previously given scopolamine alone or meperidine and propiomazine in combination, to ascertain its effect on reversing the loss of fetal heart rate variability caused by the administration of these drugs. The results of the study indicated that scopolamine indosesof 0.65 to 1.08 milligrams diminished fetal heart rate variability in all 7 patients and physostigmine reversed this loss of fetal heart rate variability in all 7 patients within 4 to 17 minutes after injection of the first dose of physostigmine. Similar results were noted in 10 patients with the combination of meperidine, 50 mg, and propiomazine, 20 mg. It seems tenable from this study that physostigmine does cross the placental barrier and enters the fetal circulation and that this usually occurs within 3 to 17 minutes with an average of approximately 9 minutes. In the healthy fetus the loss of fetal heart rate variability caused by scopolamine, meperidine or propiomazine can be reversed by the use of physostigmine and this reversal seems abrupt and clinically measurable on the fetal monitor print out.
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Resume
Effet de la physostigmine sur la baisse de variab ite de la frequence cardiaque foetale causee par la scopolamine, la meperidine et la propiomazine 17 malades trait6s cn laboratoire avaient Γβςιι de la scopolamine seule ου un melange dose de meperidine et de propiomazine, a la suite de quoi on leur a administre de la physostigmine pour observer ses effets sur le revirement deperte de variabilite de la frequence cardiaque foetale causee par la prise des medicaments precites. Les resultats des examens ont montre que la scopolamine appliquee a doses de 0,65 1,08 milligrammes fait baisser la variabilite de la frequence cardiaque foetale chez les 7 malades et que la physostigmine a renverse cette baisse chez les 7 patientes dans l' space de 4 a 17 minutes apres Tinjection de la premiere dose de physostigmine. Des resultats sim aiies ont ete observes chez les 10 malades ayant regu un melange de 50 mg de meperidine et de 20 mg de propiomazine. Cette etude laisse supposer que la physostigmine traverse la barriere placentaire pour penetrer dans la ciiculation foetale et cela, generalement, entre
